Brain Tumor Drugs Market Size, Share, Forecast 2023 to 2033

The brain tumor drug market focuses on discovering, manufacturing, and distributing drugs like carmustine, cisplatin, methotrexate, and temozolomide for treating brain tumors. Primary and secondary brain tumors originate in brain tissue, and one in every 100 US cancers spreads to the skull. Government initiatives, such as improved cancer treatment access and expanded medical education, drive demand. The increasing number of neurological disorders in children and adults also contributes to the growth of the brain tumor drug market. The brain tumor drug market is expanding due to neurological disorders, longer life expectancy, increased infection exposure, and sedentary lifestyles. Technological advancements, clinical trials, and regulatory support are driving growth, with collaboration between healthcare institutions and pharmaceutical companies fostering novel treatments. However, the high cost of drugs may impede the brain tumor drugs market.